替吉奥联合多西他赛和卡铂治疗头颈部鳞癌的临床观察  

CLINICAL OBSEVATION OF S-1 COMBINED WITH DOCETAXEL AND CISPLATIN IN THE TREATMENT OF PATIENTS WITH ADVANCED HEAD AND NECK SQUA MOUS CELL CARCINOMA

作　　者：高菁[1] 曹京燕[2] 高静[1] 

机构地区：[1]厦门大学附属第一医院头颈外科,福建厦门361003 [2]哈尔滨医科大学附属第三医院肿瘤内科,黑龙江哈尔滨150081

出　　处：《牡丹江医学院学报》2014年第6期36-38,共3页Journal of Mudanjiang Medical University

基　　金：国家自然科学基金青年项目(编号:81101758)

摘　　要：目的:观察替吉奥联合多西他赛和卡铂治疗晚期头颈部肿瘤的疗效及毒副反应。方法:采用随机、对照、开放性的临床试验设计。入选52例初治的晚期头颈部肿瘤患者,随机分为两组,实验组26例采用DCS方案化疗;对照组26例,采用多西他赛、顺铂、亚叶酸钙及氟尿嘧啶方案(DCF方案)化疗;至少3个周期后评价疗效及不良反应。结果:治疗组的近期有效率(RR)为53.8%,略优于对照组的42.3%,差异无统计学意义(P>0.05);治疗组的不良反应及严重反应发生率均明显低于对照组(P<0.05)。结论:替吉奥联合多西他赛和卡铂化疗方案治疗晚期头颈部肿瘤疗效好,不良反应可耐受。Objective：To evaluate the therapeutic and adverse effects of the combination of S -1 with Docetaxel and Cisplatin （ DCS therapeutic regimens） in the treatment for with advanced head and neck squamous cell carcinoma.Methods：A randomized, open, con-trol clinical trial was designed and 52 patients with advanced head and neck squamous cell carcinoma were randomly divided into two groups.The experimental group （26 patients） was treated using the DCS therapeutic schedules; the control group was treated with Doxtaxol, Cisplatin, Calcium Folinate and 5-FU （DCF therapeutic regimens）.The short-term efficacy and adverse reactions were evaluated after at least three treatment cycles.Results：All the 52 patients are suitable for evaluation.The tumor response rate （ RR） of the experimental group is better than that of the control group （52.8%vs.42.3%, P〉0.05）.In addition, compared with the con-trol group, occurrence rate of adverse reactions and seriou response of the experimental group were significantly lower （P〈0.05）. Conclusion：S-1 combined with Docetaxel and Cisplatin may achieve a favorable response in patients with advanced head and neck squamous cell carcinoma , and causes tolerable adverse effect without accumulative toxicity.

关 键 词：晚期头颈部肿瘤 化学治疗 替吉奥 卡铂 S-1 

分 类 号：R73[医药卫生—肿瘤]